Motor neuron-derived induced pluripotent stem cells as a drug screening platform for amyotrophic lateral sclerosis

Front Cell Dev Biol. 2022 Aug 24:10:962881. doi: 10.3389/fcell.2022.962881. eCollection 2022.

Abstract

The development of cell culture models that recapitulate the etiology and features of nervous system diseases is central to the discovery of new drugs and their translation onto therapies. Neuronal tissues are inaccessible due to skeletal constraints and the invasiveness of the procedure to obtain them. Thus, the emergence of induced pluripotent stem cell (iPSC) technology offers the opportunity to model different neuronal pathologies. Our focus centers on iPSCs derived from amyotrophic lateral sclerosis (ALS) patients, whose pathology remains in urgent need of new drugs and treatment. In this sense, we aim to revise the process to obtain motor neurons derived iPSCs (iPSC-MNs) from patients with ALS as a drug screening model, review current 3D-models and offer a perspective on bioinformatics as a powerful tool that can aid in the progress of finding new pharmacological treatments.

Keywords: 3D cell culture; amyotrophic lateral sclerosis (ALS); bioinformactics; drug screening; in vitro disease model; induced pluripotent stem cells (iPSCs); motor neuron differentiation.

Publication types

  • Review